Equities

Lipocine Inc

LPCN:NAQ

Lipocine Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.99
  • Today's Change-0.02 / -0.40%
  • Shares traded50.77k
  • 1 Year change+45.48%
  • Beta1.1675
Data delayed at least 15 minutes, as of Sep 19 2024 20:47 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

  • Revenue in USD (TTM)4.80m
  • Net income in USD-8.49m
  • Incorporated2011
  • Employees17.00
  • Location
    Lipocine Inc675 S Arapeen Dr Ste 202SALT LAKE CITY 84108-1295United StatesUSA
  • Phone+1 (801) 994-7383
  • Fax+1 (801) 994-7388
  • Websitehttps://www.lipocine.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lisata Therapeutics Inc0.00-21.07m24.54m25.00--0.6418-----2.56-2.560.004.600.00----0.00-40.16-45.97-43.61-50.47------------0.00------61.57------
Marker Therapeutics Inc3.73m-10.31m24.72m8.00--2.54--6.63-1.16-1.170.41961.090.2217--1.76465,930.00-61.30-53.74-71.74-62.25-----276.53-1,438.71----0.00---5.7674.2728.97------
Iterum Therapeutics PLC0.00-28.34m24.75m14.00---------2.00-2.000.00-0.6580.00----0.00-86.93-118.12-150.76-199.23-------890,554.10----2.06------13.64---32.09--
Promis Neurosciences Inc0.00-12.20m24.96m6.00---------0.6924-0.69240.00-0.12010.00----0.00-839.15-144.28---262.23-------2,271,047.00------------26.85------
Nuo Therapeutics Inc1.03m-2.69m25.01m----41.78--24.31-0.0622-0.06220.02370.01320.73320.9544.06---191.94-116.16-381.40-354.8479.4870.02-261.78-854.531.39-2,383.080.00--442.12-14.990.0095------
Surrozen Inc0.00-53.45m25.68m42.00--4.24-----21.74-21.740.001.890.00----0.00-98.01---110.62-------------2.050.00---100.00---19.55------
IGC Pharma Inc1.06m-13.30m25.72m67.00--3.26--24.22-0.2104-0.21040.01670.10420.08090.20288.4015,850.75-101.29-42.46-122.91-46.0760.3620.95-1,252.64-730.001.16--0.0173--47.64-23.45-12.98--53.72--
Neurosense Therapeutics Ltd0.00-11.88m26.29m16.00---------0.7299-0.72990.00-0.44880.00----0.00-350.36---5,244.59----------------------18.10------
Aeon Biopharma Inc0.00-305.52m26.48m5.00---------8.40-8.400.00-0.71440.00----0.00-6,646.10----------------9.21---------631.85------
Lipocine Inc4.80m-8.49m26.79m17.00--1.26--5.58-1.60-1.600.90123.970.1794--109.27282,407.70-31.72-39.32-34.05-45.87-----176.80-442.26----0.00---670.16---51.99------
Cue Biopharma Inc8.30m-46.96m26.93m53.00--1.25--3.25-0.9743-0.97430.17180.44450.1437--5.56156,528.30-81.32-57.45-113.52-68.41-----566.02-810.87----0.2242--340.8836.884.30------
Vyne Therapeutics Inc486.00k-27.86m27.43m10.00--0.3611--56.45-2.41-2.570.01625.150.0087----48,600.00-49.92-108.41-59.60-138.57-----5,732.31-1,907.10----0.00---11.11-47.5117.89------
Impact Biomedical Inc0.00-4.25m27.48m1.00--1.18-----0.3694-0.36940.002.030.00----0.00-9.59---15.04-------------5.120.3377---100.00--38.51------
ImmuCell Corp23.22m-4.05m28.20m74.00--1.20--1.21-0.521-0.5212.992.990.54092.3213.47293,961.10-9.43-5.16-10.50-5.5326.0540.04-17.44-12.640.7668-7.430.3243---5.909.72-131.56---1.39--
Neurobo Pharmaceuticals Inc0.00-25.90m28.86m8.00--1.48-----4.97-4.970.002.300.00----0.00-89.41-95.57-117.09-135.64------------0.00------10.72--75.54--
Data as of Sep 19 2024. Currency figures normalised to Lipocine Inc's reporting currency: US Dollar USD

Institutional shareholders

9.83%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2024219.77k4.11%
BlackRock Fund Advisorsas of 30 Jun 202489.27k1.67%
UBS Securities LLCas of 30 Jun 202456.22k1.05%
Geode Capital Management LLCas of 30 Jun 202453.18k0.99%
Renaissance Technologies LLCas of 30 Jun 202425.70k0.48%
Susquehanna Financial Group LLLPas of 30 Jun 202425.00k0.47%
SSgA Funds Management, Inc.as of 30 Jun 202418.63k0.35%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202413.16k0.25%
Two Sigma Advisers LPas of 30 Jun 202412.82k0.24%
Dimensional Fund Advisors LPas of 30 Jun 202411.87k0.22%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.